These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23811569)

  • 1. Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.
    Yamaori S; Okushima Y; Masuda K; Kushihara M; Katsu T; Narimatsu S; Yamamoto I; Watanabe K
    Biol Pharm Bull; 2013; 36(7):1197-203. PubMed ID: 23811569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.
    Yamaori S; Okushima Y; Yamamoto I; Watanabe K
    Chem Biol Interact; 2014 May; 215():62-8. PubMed ID: 24667653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells.
    Yamaori S; Kinugasa Y; Jiang R; Takeda S; Yamamoto I; Watanabe K
    Life Sci; 2015 Sep; 136():87-93. PubMed ID: 26187180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
    Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
    Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.
    Jiang R; Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
    Drug Metab Pharmacokinet; 2013; 28(4):332-8. PubMed ID: 23318708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
    Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
    Drug Metab Dispos; 2011 Nov; 39(11):2049-56. PubMed ID: 21821735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
    Yamaori S; Kushihara M; Yamamoto I; Watanabe K
    Biochem Pharmacol; 2010 Jun; 79(11):1691-8. PubMed ID: 20117100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor.
    Takeda S; Usami N; Yamamoto I; Watanabe K
    Drug Metab Dispos; 2009 Aug; 37(8):1733-7. PubMed ID: 19406952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cannabidiol-mediated cytochrome P450 inactivation.
    Bornheim LM; Everhart ET; Li J; Correia MA
    Biochem Pharmacol; 1993 Mar; 45(6):1323-31. PubMed ID: 8466552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids.
    Zhai S; Dai R; Friedman FK; Vestal RE
    Drug Metab Dispos; 1998 Oct; 26(10):989-92. PubMed ID: 9763404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol.
    Gohda H; Narimatsu S; Yamamoto I; Yoshimura H
    Chem Pharm Bull (Tokyo); 1990 Jun; 38(6):1697-701. PubMed ID: 2208386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol.
    Watanabe K; Arai M; Narimatsu S; Yamamoto I; Yoshimura H
    Biochem Pharmacol; 1987 Oct; 36(20):3371-7. PubMed ID: 3675599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.
    Chun YJ; Ryu SY; Jeong TC; Kim MY
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):389-93. PubMed ID: 11259321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiepileptic potential of cannabidiol analogs.
    Consroe P; Martin A; Singh V
    J Clin Pharmacol; 1981; 21(S1):428S-436S. PubMed ID: 7298873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol is a selective human cytochrome P450 1A1 inhibitor.
    Chun YJ; Kim MY; Guengerich FP
    Biochem Biophys Res Commun; 1999 Aug; 262(1):20-4. PubMed ID: 10448061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.
    Lo SN; Chang YP; Tsai KC; Chang CY; Wu TS; Ueng YF
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):671-80. PubMed ID: 23886934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons.
    Shimada T; Guengerich FP
    Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells.
    Joshi P; McCann GJP; Sonawane VR; Vishwakarma RA; Chaudhuri B; Bharate SB
    J Chem Inf Model; 2017 Jun; 57(6):1309-1320. PubMed ID: 28489395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2.
    Sridhar J; Ellis J; Dupart P; Liu J; Stevens CL; Foroozesh M
    Drug Metab Lett; 2012; 6(4):275-84. PubMed ID: 23506553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
    Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.